Immunovant, Inc. - Common Stock —— 资产负债表 (NASDAQ:IMVT) | MetaTrader

展开完整图表完整图表

Financials

概览声明统计

每季度年度

总资产 412.49 M515.56 M405.84 M666.37 M776.22 M957.01 M 负债总额 21.01 M45.74 M43.34 M48.61 M68.78 M104.42 M 权益总额 391.48 M469.82 M362.49 M617.76 M707.45 M852.59 M 负债及股东权益总额 412.49 M515.56 M405.84 M666.37 M776.22 M957.01 M 总债务 —————— 净债务 ——————

新闻

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT)

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV)

These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Immunovant (NASDAQ:IMVT)

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

These Two Biotech Stocks Rocketed — And One Just Broke Out

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow (NASDAQ:IMVT) 2026-04-02

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

Stifel reiterates Buy rating on OmniAb stock, cites partner growth

OmniAb 2025年第四季度业绩:营收下滑但管线项目达407个